colon cancer

They’re approved by the FDA and Medicare and inching closer to widespread adoption nationally. But how good are they at detecting colorectal cancer?

Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.

Understanding the complex three-way communication between immune cells, the gut microbiome, and cancer sheds light on why immunotherapies fail in some patients but succeed in others.